BNP Paribas Asset Management
AXSM icon

BNP Paribas Asset Management’s Axsome Therapeutics AXSM Stock Holding History

BNP Paribas Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
625
+157
+34% +$27.1K ﹤0.01% 1494
2025
Q4 		$85K Buy
468
+142
+44% +$19.8K ﹤0.01% 1516
2025
Q3 		$40K Hold
326
– – ﹤0.01% 1123
2025
Q2 		$34K Buy
+326
New +$34.5K ﹤0.01% 1280

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Asset Management's AXSM Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Axsome Therapeutics (AXSM) stake by 34% in Q1 2026, buying an estimated $27.1K and bringing the position to 625 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1494.

BNP Paribas Asset Management first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • BNP Paribas Asset Management held 625 shares of Axsome Therapeutics worth $106K as of Q1 2026.
  • BNP Paribas Asset Management bought 157 Axsome Therapeutics shares in Q1 2026, an estimated $27.1K.
  • Axsome Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1494 holding.
  • BNP Paribas Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.